Page 11 - CIRN Annual Report 2017
P. 11

CIRN NETWORKS AND THEIR PROJECTS



                                                                                                                      CIRN  •  2017 ANNUAL REPORT     9
















                                                                                                    enrollment will begin in spring 2017.



                                                                              CTN also embarked on its first African-Canadian collaboration  with a phase II Ebola vaccine in HIV-affected populations study  (ACHIV-Ebola). This international collaboration between the  International Development Research Centre (IDRC), CIRN and  Merck, with sites in Africa (Senegal, Burkina Faso) and Canada  (Montreal, Ottawa), will evaluate the safety and tolerability of  the VSV-Ebola vaccine in HIV-inf

















                                                                                             eld work)
                                                                            on salivary IgG and IgA ELISAs, with data analysis to begin in























                                                                                September 2017.  The Ebola-NML study is a 3-year NIH-led CIHR/PHAC-funded  study in Winnipeg of pre-exposure prophylaxis (PREP) in people  at increased risk of occupational (laboratory, clinical or fi exposure to Ebola virus. Participants receive a dose of VSV-Ebola  and are randomized to a booster or no booster at 18 months.  The study has Health Canada approval and will start screening in      Spring 201
   6   7   8   9   10   11   12   13   14   15   16